Autologous natural killer cell infusion as consolidation therapy after first-line chemoradiotherapy for limited-stage small-cell lung cancer: A randomized, controlled, open-label, single-center phase ...

Google didn't forget AI creators in its latest round of Gemini announcements as part of Google I/O. The company just officially revealed Gemini Omni, a new model that can "create anything from any ...

Star Wars producer Kathleen Kennedy was one of the few skeptics at the Runway AI Summit, where AI was compared to fire and the printing press just a week after Sora’s death. As Kennedy told an ...

OpenAI's nascent ads business has surpassed $100 million in annual recurring revenue less than two months after launching its pilot in the U.S., according to a spokesperson. The company said in ...

This voice experience is generated by AI. Learn more. This voice experience is generated by AI. Learn more. Pills, tablets and capsules on world map with charts blue background. International ...

The Federal Reserve's pause on rate cuts means investors can still grab attractive yields on short-duration assets. The central bank opted to keep the federal funds rate between 3.5% to 3.75% on ...

To approve leucovorin as the first treatment for CFD-FOLR1, the FDA took several highly unusual steps. (CQ-Roll Call/Getty Images) About five months after U.S. Department of Health and Human Services ...

Generate:Biomedicines has hit the public markets as the world begins to question the usefulness of AI technology. CEO Mike Nally says biology is the key to unlocking the technology’s full potential.

Feb 27 (Reuters) - Flagship-backed Generate Biomedicines' shares fell more than 6% in their Nasdaq debut on Friday, giving the drug developer a valuation of $1.91 billion, as lingering market ...

Despite wide availability of biologic drugs for asthma, use of these injectable medicines remains low — patients just dislike frequent injections. Generate Biomedicine’s lead drug candidate could ...

Generate:Biomedicines has earmarked $300 million of its IPO funds to complete a pair of phase 3 asthma trials for its anti-TSLP antibody GB-0895. (Fabrice Cabaud/Stock/Getty Images Plus) ...

Generate Biomedicines Inc. raised $400 million in an initial public offering, pricing its shares at the midpoint of the marketed range. The Somerville, Massachusetts-based drug developer sold 25 ...